Apnimed (NASDAQ:APMD – Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.51 earnings per share for the quarter, Zacks reports.
Apnimed Stock Performance
Shares of APMD stock traded up $1.34 on Tuesday, reaching $28.79. The stock had a trading volume of 380,633 shares, compared to its average volume of 378,768. Apnimed has a 1 year low of $16.12 and a 1 year high of $35.29.
Wall Street Analyst Weigh In
Several research analysts have commented on the company. Zacks Research raised Apnimed to a “hold” rating in a research note on Wednesday, August 26th. Cantor Fitzgerald assumed coverage on shares of Apnimed in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. Lifesci Capital began coverage on shares of Apnimed in a report on Tuesday, August 25th. They set an “outperform” rating and a $50.00 price target on the stock. Bank of America started coverage on shares of Apnimed in a research report on Tuesday, August 25th. They set a “buy” rating and a $41.00 price objective for the company. Finally, Wall Street Zen raised shares of Apnimed to a “hold” rating in a research note on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.33.
Insiders Place Their Bets
In other Apnimed news, major shareholder Morningside Venture Investment acquired 312,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the transaction, the insider directly owned 7,152,713 shares in the company, valued at approximately $114,443,408. The trade was a 4.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
About Apnimed
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
Recommended Stories
- Five stocks we like better than Apnimed
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
